Key takeaways
Tenofovir alafenamide (Vemlidy) and didanosine (Videx) are both antiretroviral (ARV) medications that belong to the nucleoside reverse transcriptase inhibitor (NRTI) class. They are used to treat viral infections, but they target different viruses. Tenofovir alafenamide is FDA-approved for treating hepatitis B virus (HBV) in people ages 6 and older, while didanosine was used for treating human immunodeficiency virus (HIV) before it was discontinued. Vemlidy is taken once daily with food, whereas Videx was also taken orally but is no longer available in the U.S. Vemlidy is only available as a brand-name medication, while Videx had no generic versions before being discontinued. Common side effects of Vemlidy include headache, stomach pain, and cough, while Videx had serious side effects that limited its use. Vemlidy can interact with certain medications like NSAIDs, which can increase the risk of kidney damage, whereas Videx had interactions with other HIV ARVs.
